Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Chordia Therapeutics Inc. ( (JP:190A) ).
Chordia Therapeutics has announced a change in its major shareholder structure after the exercise of its 9th Series Stock Acquisition Rights and other stock acquisition rights increased the total number of voting rights outstanding. As a result, the stake of New Life Science I Investment Limited Partnership, a venture capital fund managed by Shinsei Capital Partners, was diluted from 10.51% to 9.99% of total voting rights, meaning it no longer qualifies as a major shareholder under the 10% threshold, although it remains the second-largest shareholder by rank. The company stated that this adjustment in ownership composition, driven by new share issuance rather than share sales, will have no impact on its management or business performance, suggesting limited immediate implications for corporate control or strategy.
The most recent analyst rating on (JP:190A) stock is a Hold with a Yen119.00 price target. To see the full list of analyst forecasts on Chordia Therapeutics Inc. stock, see the JP:190A Stock Forecast page.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange Growth Market, focused on developing innovative therapeutics in the life sciences sector. The company attracts funding from venture capital and institutional investors to support its R&D-driven growth strategy in oncology and related areas.
Average Trading Volume: 977,022
Technical Sentiment Signal: Sell
Current Market Cap: Yen8.75B
For an in-depth examination of 190A stock, go to TipRanks’ Overview page.